November 20, 2006 -- CoTherix accepted a $420 million buyout offer from rival Swiss firm Actelion. Actelion will pay $13.50 for each share of CoTherix, a modest premium of 21% over the closing price for CoTherix on Friday afternoon. Both companies market drugs that treat pulmonary arterial hypertension (PAH). The resulting synergies may make a profitable product out of Ventavis, the revenue-producing PAH drug from CoTherix. We look at the deal...
